# SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

# FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 6, 2021

# OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

Nevada	001-38543	26-1265381
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
400 Water Street, Suite 200, Rochester, MI		48307
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code: <u>248.651.6568</u>		
(Former name or former address, if changed since last report)		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:		
□ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)		
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).		
Emerging growth company		
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. $\Box$		
Securities registered pursuant to Section 12(b) of the Act:		
Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock	OPRX	Nasdaq Capital Market

#### **SECTION 8 – Other Events**

#### Item 8.01 Other Events

On January 6, 2021, we issued a press release announcing our invitation to present at the H.C. Wainwright's BioConnect Conference being held virtually on January 11-14, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

# **SECTION 9 – Financial Statements and Exhibits**

# Item 9.01 Financial Statements and Exhibits

99.1 Press release, dated January 6, 2021

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# **OptimizeRx Corporation**

/s/ Douglas Baker Douglas Baker

Chief Financial Officer

Date: January 6, 2021



#### OptimizeRx to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021

**ROCHESTER, Mich.** – **January 6, 2021** – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at H.C. Wainwright's BioConnect Conference being held virtually on January 11-14, 2021.

The company's presentation will be available on-demand via the H.C. Wainwright conference portal here and in the investor relations section at investors.optimizerx.com beginning at 6:00 a.m. Eastern time on Monday, January 11.

OptimizeRx CEO, William Febbo, will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.

Management will discuss the company's expanding addressable market due to the launch of new digital health solutions, and how an increasing number of enterprise-level, recurring revenue engagements are keeping the company on track for another year of record growth.

OptimizeRx generated \$34.3 million in trailing 12-month revenue ended September 30, 2020, up 44% compared to the same year-ago period.

Register for the conference here. To schedule a one-on-one meeting, please contact your H.C. Wainwright representative. For any questions about OptimizeRx, please contact Ron Both of CMA at (949) 432-7557 or submit your request here.

#### About H.C. Wainwright

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information about H.C. Wainwright, visit www.hcwco.com.

## About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on Twitter, Linked In or visit www.optimizerx.com.

#### **Important Cautions Regarding Forward Looking Statements**

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

# OptimizeRx Contact

Doug Baker, CFO Tel (248) 651-6568 (x807) dbaker@optimizerx.com

#### **Media Relations Contact**

Maira Alejandra, Media Relations Manager Tel (754) 245-7070 malejandra@optimizerx.com.

### **Investor Relations Contact**

Ron Both, CMA Tel (949) 432-7557 oprx@cma.team